Navigation Links
New stem cell identification technology could cure breast cancer

NEW YORK, Sept. 11 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), released important information about its innovative method for destroying breast cancer cells, using stem cell technology.

GENova's approach is based on cutting-edge technology that enables us to identify the protein expression in the original cancer stem cells that give rise to tumors. This ability to identify the molecular markers of these cells is an important first step in developing new and superior cancer cures, says John Savin, VP for GENova. "By recognizing the existence of cancer stem cells, we have taken a great step towards understanding this complex disease. Now that we know how to identify the unique characteristics of these stem cells, we can develop cell-specific therapies that can eradicate them --and thus neutralize breast cancer right at the source."

The key behind GENova's biotechnology is tracing cancer cells to their origin, the very stem cells from where the first malignant cell arose. Now that they are identifiable, scientists are developing tailor-made proteins that are programmed to destroy cancerous cells, whilst leaving the healthy cells intact. GENova has targeted these bio-engineered proteins for acquisition into its growing anti-cancer drug pipeline.

In the future, this technology will also enable us to identify healthy stem cells and then develop, inject, and nurture them in such a way that they can overcome the malignant cells. Eventually, healthy stem cells will overcome the sick cells, leaving the patient cured. This novel method for treating breast cancer is far superior to existing treatments, and is the underpinning of GENova's IP (Intellectual Property) portfolio.

Development of this important biotechnology would mean a new cure for cancer, rendering disfiguring mastectomies and harmful radiation therapies obsolete.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
2. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
3. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
4. Clinical Study Proves Pollogens TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks
5. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
6. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
7. Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
8. Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
9. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
10. St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients Heart Structures
11. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
Post Your Comments:
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
Breaking Medicine News(10 mins):